Mahamaya Lifesciences IPO Details
The Mahamaya Lifesciences IPO is a book build issue with a total issue size of ₹70.44 cr, comprising of fresh issue of 5329200 equity shares., and a offer for sale of 540000 equity shares. Mahamaya Lifesciences IPO opened for subscription on Nov 11, 2025 and closed on Nov 13, 2025. Mahamaya Lifesciences IPO is set price band at ₹108 to ₹114 per share, with a lot size of 1200 shares. Minimum investment for Retail investors was ₹273,600.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on Nov 14, 2025, and listed on both the NSE and BSE on Nov 18, 2025.
Kfin Technologies Limited has been appointed as the registrar. Oneview Corporate Advisors Private Limited are the Book Running Lead Manager for the issue.
Before investing in the Mahamaya Lifesciences IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 108 – 114
- Lot Size
- 1200
- Issue Size
- ₹70.44 Cr
- Minimum Investment
- ₹273600 (2400 Shares)
- Listing Date
- 18 November 2025
Current GMP
₹0 (0.00%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Mahamaya Lifesciences Limited
Mahamaya Lifesciences Limited
Incorporated: 2002
Industry: Agrochemicals and Bioproducts
Core Activities: Manufacturing, registration, and export of crop protection and soil health management products
Company Overview
Mahamaya Lifesciences Limited is a leading agrochemical company established in 2002, engaged in the manufacturing, registration, and export of high-quality crop protection products and bioproducts. The company is dedicated to enhancing crop and soil health and supporting the farming community in improving agricultural productivity and sustainability.
The company specializes in the formulation of pesticides and the supply of bulk agrochemical products to domestic agrochemical companies as well as multinational corporations (MNCs).
Mahamaya Lifesciences imports scientifically researched molecules, registers them with the Central Insecticides Board (CIB), and markets them as technical-grade and value-added formulations. These products cater to both domestic manufacturers and global MNCs.
With a strong focus on international expansion, the company has invested in global product registrations, actively operating in markets such as the Dominican Republic, Egypt, Ethiopia, Jordan, the UAE, and Turkey. The company provides high-quality products along with comprehensive data support for regulatory registrations in these countries.
Product Portfolio
1. Bulk Formulation Sales
- Acetamiprid SP
- Buprofezin SC
- Emamectin Benzoate SG
- Imidacloprid SC
- Paraquat Dichloride SC
2. Technical Sales
- Acetamiprid Technical (99% Min)
- Atrazine Technical (95% Min)
- Imidacloprid Technical (95% Min)
- Emamectin Benzoate Technical (95% Min)
3. Branded Product Sales
Major in-house branded formulations include:
- MAYAMRIT GR
- MAYAMRIT SL
- MAYAGIBB
- UCHIT EW 370
4. Export Formulations
Key exported formulations marketed under proprietary brands:
- Wiper – Sulphur 80% WDG
- Lancha – Pendimethalin 50% EC
- Tolfen – Tolfenpyrad 15% EC
- Typic – Sulphur 80% WG
Global Presence
Mahamaya Lifesciences continues to strengthen its international footprint through product registrations and partnerships across Asia, the Middle East, and Africa, ensuring sustainable and reliable crop protection solutions for global agriculture.
Mahamaya Lifesciences IPO Promoters
- Mr. Krishnamurthy Ganesan
- Mr. Prashant Krishnamurthy
- Mrs. Lalitha Krishnamurthy
Promoters Holding
Holding Pre Issue
77.27%
Holding Post Issue
56.35%
Mahamaya Lifesciences IPO Objective
The Company Mahamaya Lifesciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Purchase of Equipment for existing Formulation plant
- Funding capital expenditure towards setting up of a new Technical manufacturing plant
- Construction of Warehouse Building and Purchase of Machinery
- Funding working capital requirement of our Company
- General Corporate purposes
Address / Contact Info
Mahamaya Lifesciences Ltd.
Unit No: DPT – 033, Ground Floor,
Plot No: 79 – 80, DLF Prime Tower,
Block, Okhla, Phase – 1
Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/
IPO Snapshot
Book Running Lead Managers
- Oneview Corporate Advisors Private Limited
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Mahamaya Lifesciences IPO is a Book-building IPO with a total issue size of ₹70.44 crore. The Mahamaya Lifesciences IPO price band is ₹108 to 114 per share. The Mahamaya Lifesciences IPO subscription opens on Tue, Nov 11, 2025, and closes on Thu, Nov 13, 2025. The Mahamaya Lifesciences IPO will be listed on the BSE. Kfin Technologies Limited is the registrar for the Mahamaya Lifesciences IPO.
The Mahamaya Lifesciences IPO opens on Tue, Nov 11, 2025 and closes on Thu, Nov 13, 2025
Mahamaya Lifesciences IPO Price Band is ₹108 to 114 per share.
Mahamaya Lifesciences IPO lot size is 1200 shares, Retail investors need a minimum investment of ₹273600 based on the upper price band
The minimum investment for Mahamaya Lifesciences IPO is ₹273600, based on one lot of 1200 shares at the upper price band of ₹114 per share.
Investors can apply for the Mahamaya Lifesciences IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Thu, Nov 13, 2025. The application amount remains blocked until the Mahamaya Lifesciences IPO allotment is finalized.
Mahamaya Lifesciences IPO issue size is ₹70.44 crores.
Mahamaya Lifesciences IPO allotment date is Wed, Jul 1, 2026.
The registrar for Mahamaya Lifesciences IPO is Kfin Technologies Limited. Investors can go to Kfin Technologies Limited website to check Mahamaya Lifesciences IPO allotment status, refund processing, and other IPO-related information.